Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.77 +1.71%

+$0.29 today

Market cap
$1.58B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 2.39M

Average 3.08M

SRPT EBITDA Margin

EBITDA as a percentage of revenue.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 51.4%

EBITDA Margin was 51.4% in Q1 FY2026, up 100.9 pp from a year earlier. On a trailing-twelve-month basis it was 5.7%, up 10.5 pp year over year. Over 3 fiscal years it widened by 34.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 22.1% for the fiscal year ending Dec 2026, up from -29.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
51.4%+108.3 pp QoQ
Last fiscal yearDec 2025
-29.5%-46.1 pp YoY
LTMMar 2026
5.7%+10.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+100.9 pp-11.1 pp-112.0 pp
1 year-46.1 pp+51.6 pp+97.8 pp
3 years+34.3 pp+27.5 pp-6.8 pp
5 years+29.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-29.5%
Year-over-year change
-46.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 EBITDA Margin of 5.7% is the 3rd highest of the 6 companies compared; the peer median is -49.3%.
  • Its year-over-year change of +10.5 pp is the 3rd highest of 6, against a peer median of -30.5 pp.
  • Over three fiscal years its change of +34.3 pp compares with a peer median of +106.3 pp.
SRPT Competitors Peer median
EBITDA Margin for SRPT and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202624.0% +30.9 pp+106.3 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-243.2% -144.4 pp+3681.3 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-581.9% +549.6 pp+308.9 pp
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
DSGNDesign Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding SRPT) -49.3%-30.5 pp+106.3 pp

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.